Clinical trialNCT06514794RecruitingPhase 2Interventional

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

SponsorAllotera TherapeuticsEnrollment125Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Cherry Thomas, MD
Allotera Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Peter Mac Callum Cancer Institute
Melbourne, Victoria, Australia
Ashish Bajel, M.D.
Recruiting
Royal Children'S Melbourne
Melbourne, Victoria, Australia
Recruiting

United States

City of Hope
Duarte, California, United States
Ibrahim Aldoss, MD
Recruiting
Children'S Hospital Los Angeles
Los Angeles, California, United States
Deepa Bhojwani, MD
Recruiting
Colorado Blood Cancer Institute
Denver, Colorado, United States
Alireza Eghtedar, M.D.
Recruiting
Children'S National Hospital
Washington D.C., District of Columbia, United States
Keri Toner, MD
Recruiting
H. Lee Moffitt Cancer Center and Research Institute Hospital
Tampa, Florida, United States
Rawan Faramand, M.D.
Recruiting
Children'S Hospital of Atlanta
Atlanta, Georgia, United States
Muna Qayed, MD
Recruiting
Washington University Saint Louis
St Louis, Missouri, United States
Recruiting
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Recruiting
Oncology Hematology Care
Cincinnati, Ohio, United States
Ahmed Galal, MD
Recruiting
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Recruiting
Tristar Bone Marrow Transplant / Sarah Cannon Transplant & Cellular Therapy
Nashville, Tennessee, United States
Stephen Strickland, M.D.
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Elias Jabbour, M.D.
Recruiting
Sarah Cannon Transplant and Cellular Therapy Methodist Hospital
San Antonio, Texas, United States
Nosha Farhadfar, M.D.
Recruiting
Sarah Cannon, Virginia Oncology Associates
Norfolk, Virginia, United States
Gary L. Simmons, D.O.
Recruiting
Seattle Children'S Hospital
Seattle, Washington, United States
Adam Lamble, M.D.
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

WU-CART-007 →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2025
Primary completion: 30 Dec 2026
Completion: 30 Dec 2028
Last update posted: 6 Aug 2026
Registered enrollment: 125
Registry id: NCT06514794

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.